{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:40Z","timestamp":1787010160651,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nivolumab is the human programmed cell death-1 (PD-1)-blocking antibody showing significant effect in many refractory cancers. However, little is known about its risks of hematological toxicities, rare but clinically serious and potentially life-threatening adverse events. We want to explore whether nivolumab can increase the risks of hematological toxicities compared with other immunotherapy or chemotherapy drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>The databases of PubMed, Embase, Web of science, and CNKI were searched. We used the medical subject heading terms \u201cNivolumab\u201d plus keyword \u201cNivolumab\u201d to search studies published from August 1990 to October 2021. For the included articles, we calculated the relative risks and the corresponding 95% confidence intervals (CIs) for the risks of anemia, neutropenia, and leukopenia in patients treated with nivolumab versus control drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five original articles on the nivolumab trials were identified with 2399 patients enrolled in this meta-analysis. The relative risks of anemia, neutropenia, and leukopenia were 0.343 (95% CI: 0.177\u20130.663;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001), 0.020 (95% CI: 0.008\u20130.053;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000), and 0.054 (95% CI: 0.015\u20130.191;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The PD-1 inhibitor-nivolumab did not increase the risk of anemia, neutropenia and leukopenia. It may enhance awareness about lower risks of hematological toxicities when choosing nivolumab as PD-1 inhibitor among clinicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000032393","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T08:01:38Z","timestamp":1672387298000},"page":"e32393","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"given":"Zuolin","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, No.926 Hospital, Joint Logistics Support Force of PLA, Yunnan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-454X","authenticated-orcid":false,"given":"Hongna","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Officers, General Hospital of Northern Theater Command, Shenyang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2021.11.012","article-title":"Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance.","volume":"40","author":"Newell","year":"2021","journal-title":"Cancer Cell"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e002843","DOI":"10.1136\/jitc-2021-002843","article-title":"An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.","volume":"9","author":"Zuo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.3390\/cancers13246326","article-title":"Anti-PD-1 therapy with adjuvant ablative fractional laser improves anti-tumor response in basal cell carcinomas.","volume":"13","author":"Olesen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e1085146","DOI":"10.1080\/2162402X.2015.1085146","article-title":"PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity.","volume":"5","author":"Lim","year":"2016","journal-title":"Oncoimmunology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage iv or recurrent non-small-cell lung cancer.","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.21.01570","article-title":"Adaptive dosing of nivolumab + ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (The ADAPT-IT Study).","volume":"40","author":"Postow Michael","year":"2021","journal-title":"J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtho.2021.07.029","article-title":"Nivolumab plus ipilimumab should be the standard of care for first-line unresectable epithelioid mesothelioma.","volume":"17","author":"Baas","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/21645515.2016.1175694","article-title":"Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers.","volume":"12","author":"Rajan","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2021.11.015","article-title":"T cell immune awakening in response to immunotherapy is age-dependent.","volume":"162","author":"Salih","year":"2021","journal-title":"Eur J Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2217\/fon.15.52","article-title":"Nivolumab: targeting PD-1 to bolster antitumor immunity.","volume":"11","author":"Brahmer","year":"2015","journal-title":"Future Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"100353","DOI":"10.1016\/j.esmoop.2021.100353","article-title":"IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.","volume":"7","author":"Molinier","year":"2021","journal-title":"ESMO Open"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e2134299","DOI":"10.1001\/jamanetworkopen.2021.34299","article-title":"Comparative effectiveness of atezolizumab, nivolumab, and docetaxel in patients with previously treated non-small cell lung cancer.","volume":"4","author":"Ramagopalan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"17588359211019642","DOI":"10.1177\/17588359211019642","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:25:38Z","timestamp":1746318338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":20,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032393","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}